loader
Please Wait
Applying Filters...

Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for r1_cep_2000_338___rev_01 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Sanofi

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    PharmaCompass Sponsored Ads

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Sanofi-Aventis S.p.A. Brindisi IT (1)

    filter

    01 Teicoplanin (1)

    filter

    01 Italy (1)

    filter

    01 Withdrawn by Holder (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    Sanofi-Aventis S.p.A. Brindisi IT

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Teicoplanin

    PDF Supplier PDF
    URL Supplier Web Content
    R1-CEP 2000-338 - Rev 01
    Withdrawn by Holder
    TSE
    2007-03-01
    2022-07-19
    2358
    Sanofi Company Banner

    Vietnam Medi Pharm 2024

    Not Confirmed

    envelop Contact Supplier

    Looking for Certificates of Suitability (CEPs) for R1-CEP 2000-338 - Rev 01 of Sanofi-aventis S.p.a. Brindisi It

    Looking for Certificates of Suitability (CEPs) for R1-CEP 2000-338 - Rev 01 of Sanofi-aventis S.p.a. Brindisi It 1

    20

    Sanofi-aventis S.p.a. Brindisi It, based in France, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

    They are recognized for Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    One of their significant offerings is Teicoplanin, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2000-338 - Rev 01

    This TSE Type CEP, issued on March 01, 2007, remains in force until July 19, 2022, ensuring its reliability within the pharmaceutical industry.

    Substance Number 2358 associated with this CEP further emphasizes

    Post Enquiry
    POST ENQUIRY